The interventional cardiology devices market demand is expected to grow at an 8.4% CAGR from USD 16.4 Billion in 2022 to USD 36.9 Billion by 2032.
The rapid growth of the elderly population, which has led to an increase in the prevalence of coronary artery disease, the approval of new and advanced products, and the rising incidence of diabetes are all driving growth in the interventional cardiology devices market.
However, the availability of alternative therapies, as well as product failures and recalls, are the key factors expected to stymie growth in the interventional cardiology devices market over the forecast period.
Despite the fact that emergency and outpatient treatments are available in cardiology departments, the number of hospital visits has declined considerably in the last six months. As a result of statewide lockdowns and social distancing methods, patient visits have been dramatically reduced. This has resulted in even lower interventional cardiology product sales.
Request a Sample of this Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-14684
Many of the leading firms in the interventional cardiology devices market, including Boston Scientific, Medtronic, and Abbott, have reported revenue reductions for the second and third quarters of 2020.
Every year, 170,000 people in the United Kingdom die as a result of heart and circulation diseases. With such a huge patient population and such a high mortality rate, demand for interventional cardiology equipment is expected to expand in the coming years.
Other risk factors that fuel the demand for interventional cardiology equipment include diabetes and hypertension. Diabetes is more likely to be linked to other conditions that raise the risk of coronary heart disease. Over time, high blood sugar levels may affect the blood vessels that regulate the heart.
In all major areas, the prevalence of interventional cardiology illnesses is expected to rise as the world’s old population grows. This will increase demand for interventional cardiology devices in key interventional cardiology device markets during the projection period.
India, China, and Brazil are mainly untapped markets for interventional cardiology devices. Diabetes incidence and a large geriatric population in these and other emerging interventional cardiology device markets offer significant potential opportunities for the interventional cardiology device industry.
Of all angiography catheters, the type category accounted for the greatest share of the interventional cardiology devices market. This is because of the high and rising prevalence of coronary artery disease (CAD), as well as growing awareness of the benefits of CAD early identification.
North America has the largest regional share of the interventional cardiology devices market. A significant chunk of North America might be attributed to factors such as growing diabetes prevalence, an ageing population, reimbursement availability, and the presence of all major corporations.
Get In Touch With Our Team For Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-14684
KEY TAKEAWAYS:
- In the product sector, Angioplasty Stents from the marketing attribution software market is anticipated to flourish at the quickest CAGR of 8% through 2032.
- With a CAGR of 7.9% through 2032, North America is predicted to grow significantly in the region segment of the marketing attribution software market.
- The market size for marketing attribution software market in the United States is expected to reach US$ 12.9 Billion by 2032, growing at a CAGR of 8.2% through 2032.
- China is anticipated to reach a market size of US$ 2.7 Billion in marketing attribution software by 2032, with a CAGR of 7.8% through 2032.
- UK’s marketing attribution software market is anticipated to be worth US$ 1.5 Billion by 2032, with a CAGR of 7.5% through 2032.
- Japan is expected to have a market size for marketing attribution software of US$ 2.1 Billion by 2032, with a CAGR of 6.7% through 2032.
- By 2032, South Korea is expected to reach a market size of US$ 1.3 Billion in marketing attribution software, with a CAGR of 6.2% through 2032.
COMPETITIVE LANDSCAPE:
Medtronic (US), Boston Scientific Corporation (US), Abbott (US), Edward Lifesciences Corporation (US), Cardinal Health (US), iVascular (Spain), Becton, Dickinson, and Company (US), B. Braun Melsungen (Germany), Terumo Corporation (Japan), Biosensors International Group (Singapore), and BIOTRONIK SE & Co. KGaA are prominent interventional cardiology devices market players (Germany).
Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-14684
Key Segments
By Product:
- Angioplasty Balloons
- Old/Normal Balloons
- Drug-eluting Balloons
- Cutting and Scoring Balloons
- Angioplasty Stents
- Drug-eluting Stents
- Bare-mental Stents
- Bioabsorbable Stents
- Structural Heart Devices
- Aortic Valve Therapy Devices
- Other Therapy Devices
- Catheters
- Angiography Catheters
- Guiding Catheters
- IVUS/OCT Catheters
- Plaque Modification Devices
- Atherectomy Devices
- Thrombectomy Devices
- Hemodynamic Flow Alteration Devices
- Embolic Protection Devices
- Chronic Total Occlusion Devices
- Other Devices
- Guidewires
- Vascular Closure Devices
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs